Literature DB >> 6428208

Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.

J E Shaw.   

Abstract

This article describes in vitro and in vivo performance of two transdermal drug delivery systems. Transderm -Nitro delivers nitroglycerin for the treatment and prevention of angina for 24 hours following a single application. In a three-way crossover study comparing Transderm -Nitro with two other transdermal nitroglycerin products, mean plasma levels of drug were similar 0.5 and 6 hours after application; however, with Transderm -Nitro the area under the plasma concentration curve was highest and the coefficient of variation was least. A transdermal therapeutic system for delivering clonidine ( Catapres -TTS) is used for the treatment of hypertension. In a two-way crossover study comparing Catapres -TTS and oral Catapres , plasma levels of clonidine with use of the transdermal system reached a steady-state value in 2 to 3 days and remained steady for the duration of the wearing period; plasma levels with oral Catapres , however, fluctuated markedly. The ratio of maximum to minimum plasma levels during a dosing interval was 2 for oral Catapres and approximately 1 for Catapres -TTS. The potential use of intact skin as a route of entry for controlled delivery of drugs to the systemic circulation is promising.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428208     DOI: 10.1016/0002-8703(84)90578-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin.

Authors:  T O Klemsdal; K Gjesdal; J E Bredesen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses.

Authors:  N J Sarlis; O Caticha; J L Anderson; C Kablitz; F S Shihab
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

3.  Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

4.  A diffusion-diffusion model for percutaneous drug absorption.

Authors:  K Kubota; T Ishizaki
Journal:  J Pharmacokinet Biopharm       Date:  1986-08

Review 5.  Pharmacokinetic considerations in the use of newer transdermal formulations.

Authors:  G Ridout; G C Santus; R H Guy
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 6.  The USA experience with the clonidine transdermal therapeutic system.

Authors:  J F Burris
Journal:  Clin Auton Res       Date:  1993-12       Impact factor: 4.435

Review 7.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

8.  Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.

Authors:  William R Ravis; Alejandro Llanos-Cuentas; Nestor Sosa; Mara Kreishman-Deitrick; Karen M Kopydlowski; Carl Nielsen; Kirsten S Smith; Philip L Smith; Janet H Ransom; Yuh-Jing Lin; Max Grogl
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

10.  The efficacy of a transdermal formulation of clonidine in mild to moderate hypertension and its effects on the arterial and venous vasculature of the forearm.

Authors:  A Achimastos; X Girerd; A C Simon; I Pithois-Merli; J Levenson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.